Jubilant Pharmova soars as its arm gets EIR from USFDA for radiopharmaceuticals manufacturing facility Montreal Canada
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Jubilant Pharmova is currently trading at Rs. 348.65, up by 11.75 points or 3.49% from its previous closing of Rs. 336.90 on the BSE.
The scrip opened at Rs. 340.00 and has touched a high and low of Rs. 350.00 and Rs. 335.40 respectively. So far 28764 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 690.00 on 01-Sep-2021 and a 52 week low of Rs. 317.65 on 21-Jun-2022.
Last one week high and low of the scrip stood at Rs. 350.00 and Rs. 335.40 respectively. The current market cap of the company is Rs. 5366.18 crore.
The promoters holding in the company stood at 50.68%, while Institutions and Non-Institutions held 24.09% and 25.24% respectively.
Jubilant Pharmova’s wholly owned subsidiary -- Jubilant Draximage Inc., has received the Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for its radiopharmaceuticals manufacturing facility at Montreal Canada in respect of the inspection conducted by the regulatory agency from June 6, 2022 to June 10, 2022. With the receipt of the EIR, the inspection stands successfully closed.
Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.
